Skip to Content

MRI Volumetry Accurately Differentiates bvFTD from Early-Onset Alzheimer’s Disease

Los Angeles, Calif. — A recent study published in the Journal of Alzheimer’s Disease (DOI: 10.3233/JAD-215667) demonstrates that volumetric MRI quantification can reliably differentiate behavioral variant frontotemporal dementia (bvFTD) from early-onset Alzheimer’s disease (EOAD).

Both bvFTD and EOAD are leading causes of neurodegenerative dementia in people aged 50–65, and both are frequently misdiagnosed when relying on clinical criteria alone. The study highlights how AI-enabled volumetric MRI software such as Neuroreader® can dramatically improve diagnostic accuracy.

Study Overview

  • Authors: Somayeh Meysami, M.D., Cyrus A. Raji, M.D., Ph.D., and Mario F. Mendez, M.D., Ph.D.
  • Design: Two comparable groups by age and sex—one diagnosed with bvFTD, the other with EOAD.
  • Method: Brain MRI scans analyzed using two volumetric software tools: volBrain and Neuroreader®.
  • Objective: To determine if volumetric quantification can distinguish bvFTD from EOAD more accurately than clinical assessment.

Key Findings

  • Traditional clinical criteria alone often lead to misdiagnosis between bvFTD and EOAD.
  • Neuroreader® achieved 99.3% accuracy in differentiating between the two conditions (based on ROC analysis).
  • Distinct atrophy patterns were visible on volumetric MRI that are difficult to identify through standard visual inspection.

Why This Matters

  • bvFTD vs. EOAD misdiagnosis: Both disorders present with overlapping symptoms in midlife, often confusing clinicians.
  • Volumetric MRI provides objective, data-driven insights to guide diagnosis.
  • Earlier and more accurate diagnosis → better treatment planning, clinical trial selection, and patient outcomes.

Conclusion

This study confirms that volumetric brain MRI analysis offers superior accuracy in differentiating bvFTD from EOAD, compared to clinical evaluation alone. Tools like Neuroreader® represent a critical advancement in AI-enabled neuroimaging, supporting clinicians in reducing misdiagnosis and improving care for patients with neurodegenerative dementias.

🔗 Read the full article in the Journal of Alzheimer’s Disease


Do you want to know more about our software?

Fill out the form below and we will get back to you as soon as possible.

Submit